WEBULL
News
ZBIO
26.14
+3.40%
0.86
Weekly Report: what happened at ZBIO last week (0302-0306)?
Weekly Report · 20h ago
The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Obexelimab’s Commercial Pivot And Cash War Chest
Simply Wall St · 6d ago
Weekly Report: what happened at ZBIO last week (0223-0227)?
Weekly Report · 03/02 10:26
Weekly Report: what happened at ZBIO last week (0216-0220)?
Weekly Report · 02/23 10:26
A Look At Zenas BioPharma (ZBIO) Valuation As Obexelimab Shows Strong ACTRIMS 2026 Efficacy Data
Simply Wall St · 02/23 03:27
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires
Reuters · 02/20 21:15
ZENAS BIOPHARMA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/20 21:15
Zenas BioPharma added to Best Ideas List at Wedbush
TipRanks · 02/18 11:55
Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next
Simply Wall St · 02/16 12:20
Weekly Report: what happened at ZBIO last week (0209-0213)?
Weekly Report · 02/16 10:26
Zenas BioPharma Adopts Amended Short-Term Incentive Plan
TipRanks · 02/13 22:20
Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares
Reuters · 02/13 22:07
Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees
Reuters · 02/13 21:59
Assessing Zenas BioPharma (ZBIO) Valuation After Positive MoonStone Phase 2 Results In Multiple Sclerosis
Simply Wall St · 02/13 15:28
Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)
TipRanks · 02/13 13:17
Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
Dow Jones · 02/10 12:52
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
Benzinga · 02/10 12:41
Zenas BioPharma: Advancing Autoimmune Pipeline and Obexelimab’s Differentiated MS Profile Support Buy Rating and $44 Target
TipRanks · 02/10 12:25
Zenas Biopharma Highlights Results From Phase 2 MoonStone Trial Of Obexelimab In RMS In Late-Breaking Oral Presentation At ACTRIMS Forum 2026
Benzinga · 02/09 12:15
Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions
Reuters · 02/09 12:05
More
Webull provides a variety of real-time ZBIO stock news. You can receive the latest news about Zenas BioPharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.